<DOC>
	<DOC>NCT01251835</DOC>
	<brief_summary>This study will assess how rifampin will affect the blood levels of sitaxsentan. Safety of sitaxsentan given alone and with rifampin will also be assessed.</brief_summary>
	<brief_title>Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<criteria>Healthy male subjects and/or women of nonchild bearing potential. Subjects between the ages of 21 and 55 years, inclusive. Signed informed consent. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. Has hepatic dysfunction. Has history of excessive alcohol and tobacco use.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Sitaxsentan</keyword>
	<keyword>Rifampin</keyword>
	<keyword>Drug Interaction</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>